HEPA — Hepion Pharmaceuticals Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Kala, Carnival Corp, CrowdStrike, Diffusion
U.S. STOCKS ON THE MOVE-Socket Mobile, bluebird bio, AMC Entertainment, Southwest Airlines
Hepion Pharma plunges on deep-discounted share offering
Brief: Hepion Announces Pricing Of Public Offering
U.S. STOCKS ON THE MOVE-AMC Entertainment, Mastercard, Fox Corp
U.S. STOCKS ON THE MOVE-Protalix, WiMi Hologram Cloud
U.S. STOCKS ON THE MOVE-Acadia Healthcare, Bionano Genomics, Altimmune, FinTech Acquisition
U.S. STOCKS ON THE MOVE-JD.com, Hepion, Pfizer Inc
Hepion: Rises on positive NASH drug data
Brief: Hepion Pharma Announces Positive Top Line Data For Low Dose Crv431 In Phase 2A 'Ambition' Clinical Trial For Treatment Of Advanced Nash
Hepion: Rises on FDA clearance for COVID-19 drug candidate study
Brief: Hepion Pharmaceuticals Announces FDA Clearance Of IND Application For CRV431 For Covid-19
Brief: Hepion Pharmaceuticals Completes 75 Mg Crv431 Dosing, Initiates 225 Mg Dosing In Phase 2A 'Ambition' Clinical Trial For Nash
Brief: Orin Hirschman Reports 6.9% Passive Stake In Hepion Pharmaceuticals Inc
Brief: Empery Asset Management Reports Passive Stake Of 6.91% In Hepion Pharmaceuticals
Brief: Hepion Pharma Says Results From Translational Research Study In Which CRV431 Decreased Formation Of A Novel Class Of Human Blood Platelets
Brief: Hepion Pharma Data Safety Monitoring Board Recommends Continuation Of Phase 2a Ambition Clinical Trial For Treatment Of Advanced NASh
Brief: Hepion Pharmaceuticals Files For Offering Of Up To 10.14 Mln Shares Of Common Stock
Brief: Hepion Pharmaceuticals Completes First Cohort Enrollment In Phase 2A 'Ambition' Clinical Trial